Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2001-1-10
pubmed:abstractText
In this study, the utility of DT388-granulocyte-macrophage colony-stimulating factor (GM-CSF) for the ex vivo purging and direct administration to patients with acute myeloid leukemia (AML) is tested using clonogenic assays, long-term cultures (LTC), and NOD/SCID mice as assays for leukemic progenitors. We compare the ability of 24-hour exposure to 0.3 microg/mL (4 nM) DT388-GM-CSF to kill AML colony forming cells (CFC) and the more primitive AML progenitors detected after 6 weeks in stromal cocultures (AML LTC-initiating cells or AML LTC-IC) and after 8 weeks in NOD/SCID mice.AML samples (n = 10), expressing a mean of 35 to 1466 GM-CSF receptors/blast, showed mean (range) percent kills of AML CFC and LTC-IC of 61 (17-98) and 46 (0-94) respectively with a direct correlation (r = 0.69) between the % kills detected in the in vitro assays. Among 5 evaluable samples the percent reduction in AML cell engraftment in NOD/SCID marrow following ex vivo DT388-GM-CSF treatment varied from 38% to 100%. 40% to 56% of normal bone marrow CFC and 31% to 48% of normal LTC-IC survived the same ex vivo treatment (n = 3). In subsequent experiments, NOD/SCID mice received AML blast cell injections intravenously followed in 24 hours by 1.5 microg DT388-GM-CSF daily intraperitoneally for 5 days. A reduction of marrow blast cells was seen with 7 of 9 samples tested 4 to 12 weeks post one course of toxin. Repeating the 5-day course of toxin 2 or 3 times at 4-week intervals did not improve the response, while delaying administration until 4 to 8 weeks post AML cell injection reduced the toxin's effectiveness (n = 5).This fusion toxin may prove useful for in vitro purging of stem cell harvests from selected AML patients and for direct administration to such patients.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0301-472X
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1390-400
pubmed:dateRevised
2009-11-3
pubmed:meshHeading
pubmed-meshheading:11146161-Animals, pubmed-meshheading:11146161-Bone Marrow, pubmed-meshheading:11146161-Bone Marrow Purging, pubmed-meshheading:11146161-Cell Death, pubmed-meshheading:11146161-Cytogenetic Analysis, pubmed-meshheading:11146161-Diphtheria Toxin, pubmed-meshheading:11146161-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:11146161-Hematopoietic Stem Cells, pubmed-meshheading:11146161-Humans, pubmed-meshheading:11146161-In Situ Hybridization, Fluorescence, pubmed-meshheading:11146161-Leukemia, Myeloid, Acute, pubmed-meshheading:11146161-Mice, pubmed-meshheading:11146161-Mice, Inbred NOD, pubmed-meshheading:11146161-Mice, SCID, pubmed-meshheading:11146161-Neoplasm Transplantation, pubmed-meshheading:11146161-Receptors, Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:11146161-Recombinant Fusion Proteins, pubmed-meshheading:11146161-Spleen, pubmed-meshheading:11146161-Tumor Cells, Cultured
pubmed:year
2000
pubmed:articleTitle
Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells.
pubmed:affiliation
Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't